Publications for Anna-Lotta Hallbeck
Co-author map based on ISI articles 2007-

Publications mentioned in social media 3 times*

Keywords

tyrosine treatment tgf-alpha tgf-a tgf-<img synovial src"http//wwwinformaworldcom/cache/entities/14/000000/ffffff/arial/md/03b1png" receptor mrna melanoma malignant m kinase inhibitor gefitinib egf-r cells canertinib 11q13 />

Journal Articles

Elin Karlsson, Gizeh Pérez-Tenorio, Risul Amin, Josefine Bostner, Lambert Skoog, Tommy Fornander, Dennis C Sgroi, Bo Nordenskjöld, Anna-Lotta Hallbeck and Olle Stål
  The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials.
 
Altmetric usage: 2

  Breast Cancer Research, 2013, 15(5), R96.
   Fulltext  PDF  

Elin Karlsson, Marie Ahnström, Josefine Bostner, Gizeh Perez-Tenorio, Birgit Olsson, Anna-Lotta Hallbeck and Olle Stål
  High-Resolution Genomic Analysis of the 11q13 Amplicon in Breast Cancers Identifies Synergy with 8p12 Amplification, Involving the mTOR Targets S6K2 and 4EBP1
 
Altmetric usage: 1

  Genes, Chromosomes and Cancer, 2011, 50(10), 775-787.
   Fulltext  PDF  
 Web of Science® Times Cited: 11

Emelie Djerf, Cecilia Trinks, Henrik Green, Avni Abdiu, Anna-Lotta Hallbeck, Olle Stål and Thomas Walz
  The pan-ErbB receptor tyrosine kinase inhibitor canertinib promotes apoptosis of malignant melanoma in vitro and displays anti-tumor activity in vivo
  Biochemical and Biophysical Research Communications - BBRC, 2011, 414(3), 563-568.
 Web of Science® Times Cited: 1

Cecilia Trinks, Emelie A. Severinsson, Birgitta Holmlund, Anna Gréen, Henrik Green, Jan-Ingvar Jönsson, Anna-Lotta Hallbeck and Thomas Walz
  The pan-ErbB tyrosine kinase inhibitor canertinib induces caspase-mediated cell death in human T-cell leukemia (Jurkat) cells
  Biochemical and Biophysical Research Communications - BBRC, 2011, 410(3), 422-427.
 Web of Science® Times Cited: 1

Cecilia Trinks, Emelie Djerf, Anna-Lotta Hallbeck, Jan-Ingvar Jönsson and Thomas Walz
  The pan-ErbB receptor tyrosine kinase inhibitor canertinib induces ErbB-independent apoptosis in human leukemia (HL-60 and U-937) cells
  BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2010, 393(1), 6-10.
 Web of Science® Times Cited: 6

Emelie Djerf, Cecilia Trinks, Avni Abdiu, Lena Thunell, Anna-Lotta Hallbeck and Thomas M Walz
  ErbB receptor tyrosine kinases contribute to proliferation of malignant melanoma cells: inhibition by gefitinib (ZD1839)
  Melanoma research, 2009, 19(3), 156-166.
 Web of Science® Times Cited: 19

Anna-Lotta Hallbeck, Thomas M. Walz, Åke Wasteson and Annelie Lindström
  Cooperation of endogenous HER-family members in synovial sarcoma cells: stimulation of HER-2/ErbB2 is dependent on EGFR activation
  , 2007, , .

Anna-Lotta Hallbeck, Thomas M. Walz, Kristina Briheim and Åke Wasteson
  TGF-alpha and ErbB2 production in synovial joint tissue: increased expression in arthritic joints
  Scandinavian Journal of Rheumatology, 2005, 34(3), 204-211.
 Web of Science® Times Cited: 21

Anna-Lotta Hallbeck, Thomas M. Walz and Åke Wasteson
  Interleukin-6 enhances transforming growth factor-alpha mRNA expression in macrophage-like human monocytoid (U-937-1) cells
  Bioscience Reports, 2001, 21(3), 325-339.
 Web of Science® Times Cited: 8

Ph.D. Theses

Elin Karlsson
  Clinical potential of the mTOR effectors S6K1, S6K2 and 4EBP1 in breast cancer
  2014.


  Fulltext PDF

Emelie Severinsson
  Experimental studies on ErbB targeted therapy in malignant melanoma
  2012.


  Fulltext PDF

Cecilia Trinks
  Canertinib-induced leukemia cell death signaling: effects of a pan-ERBB inhibitor
  2012.


  Fulltext PDF

Anna-Lotta Hallbeck
  Studies of transforming growth factor alpha in normal and abnormal growth
  2007.


  Fulltext PDF

Licentiate Theses

Emelie Djerf
  Studies on the effect of ErbB tyrosine kinase inhibitors on malignant melanoma growth and survival in vitro
  2009.


  Fulltext PDF

* Social media data based on publications from 2011 to present and with a DOI; data delivered by Altmetric.com.